Skip to main content
SpringerLink
Log in

Amine precursor amino acid therapy: From neurochemical basis to clinical aspects

  • Original Articles
  • Published:
Neurochemical Research Aims and scope Submit manuscript

Abstract

The particulars regarding the amine precursor therapy for treatment of neuropsychiatric disorders and their neurochemical background are described historically. Furthermore, peculiar or artificial amino acids which are metabolized into the brain amine or their derivatives and promised their clinical application are also introduced.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sano, I. 1971. “Precursor Therapy” with active amines—Treatment of depression by 5-HTP (L-5-hydroxytriptophan). Folia Psychiat. Neurol. Japon. 73:809–815.

    CAS  Google Scholar 

  2. Sano, I., and Taniguchi, K. 1971. “Precursor Therapy” with active amines—Treatment of Parkinson's disease by 5-HTP (L-5-hydroxytriptophan), 73:835–839.

  3. Sano, I. 1960. Biochemistry of extrapyramidal motor system. Shinkeikenkyu no Shinpo 5:42–48.

    Google Scholar 

  4. Ehringer, H., and Hornykiewics, O. 1960. Verteilung von Noradrenalin im Dopamin (3-hydroxytriptamin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wochschr. 38:1236–1240.

    Article  CAS  Google Scholar 

  5. Barbeau, A. 1961. Proc. of International Congress of Neurology, Rome, Vol. 2, 925, Soseita Grafica Romana, Rome.

    Google Scholar 

  6. Birkmayer, W. Z., and Hormykiewicz, O. 1961. Der L-3,4-Diokyphenylalanine (=DOPA)-Effect bei der Parkinson-Akinese. Wien. Klin. Wochschr. 45:787–788.

    Google Scholar 

  7. Cotzais, G. C., Von Woert, M. H., and Sciffer, L. M. 1967. Aromatic amino acids and modification of parkinsonism. New Engl. J. Med. 276:374–378.

    Article  Google Scholar 

  8. Yarh, M. D., Duvoisin, R. C., Sehear, M. J., Barrett, R. E., and Hoehn, M. M. 1969. Treatment of Parkinsonism with levodopa. Arch. Neurol. 21:343–354.

    Google Scholar 

  9. Everett, G. M., and Toman, J. P. E. 1959. Mode of action of Rauwolfia alkaloid and motor activity. In: Biological Psychiatry, Vol. 1, ed. by Masserman J. H., 75, Grune and Stratton, New York-London.

    Google Scholar 

  10. Robins, E., and Hartman, B. K. 1972. Biochemical theories of mental disordersin: Eigel G. J., Albers R. W., Agranoff B. W. and Katzman R. ed. Basic Neurochemistry, 1st Ed., 607–644, Littel Brown and Company, Boston.

    Google Scholar 

  11. Nakajima, T., Kudo, Y., and Kaneko, Z. 1978. Clinical evaluation of 5-hydroxy-L-triptophan as an antidepressant drug. Folia Psychiat. Neurol. Japon. 32:223–230.

    CAS  Google Scholar 

  12. Angst, J., Woggon, B., and Schoef, J. 1977. The treatment of depression with L-5-hydroxytriptophan versus imipramine. Arch. Psychiat. Nerven Kr. 224:175–186.

    CAS  Google Scholar 

  13. Hornykiewicz, O. 1963. Die topische Lokalization und des Verhalten von Noradrenalin und Dopamin (3-Hydroxytriptamin) in der Substantia nigra des normalen und Parkinson Kranken Menschen. Wien. Klin. Wochschr. 75:309–312.

    CAS  Google Scholar 

  14. Johansson, B., and Roos, B. E. 1967. 5-Hydroxyindoleacetic acid and homovanilic acid levels in the cerebrospinal fluid of healthy volunteers, and patients with Parkinson's syndrome. Life Sci. 6: 1449–1454.

    Article  PubMed  CAS  Google Scholar 

  15. Poirier, L. J., and Sourkes, T. L. 1965. Influence of the substantia nigra on the catecholamine content of the striatum. Brain 88:181–192.

    PubMed  CAS  Google Scholar 

  16. Goldstein, M., Battista, A. F., Nakatani, S., and Anagnoste B. 1966. The effects of centrally active drugs in monkeys with mesencephalic lesions. Proc. Natl. Acad. Sci. 63:1114–1116.

    Google Scholar 

  17. Mesa, I., Court, J., Fuengalida, S., Papavasilious, P. S., and Cotzias, G. C. 1970. Modification of chronic manganese poisoning treatment with L-DOPA and 5-hydroxytryptophan. New Engl. J. Med. 282:5–10.

    Article  Google Scholar 

  18. Chase, T. N. 1970. Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism. Neurol. 20, Suppl. Pharmacologic and clinical experience with levodopa: A symposium, 36–40.

  19. Taniguchi, K. 1973. Amine precursor therapy. J. Clinical Science 9:1313–1320.

    Google Scholar 

  20. Nakajima, T. 1976. Biochemistry of Parkinson's disease. Nihonrinsho 43:2735–2740.

    Google Scholar 

  21. Jepson, J. B., Lovenberg, W., Zaltzman, P. Oates, S., Sjoerdsma, A., and Undenfriend, S. 1960. Amine metabolism studies in normal and phenylketonuric humans by monoamine oxidase inhibitor. Biochem. J. 74, 5p.

  22. Nakajima, T., Kakimoto, Y., and Sano, I. 1964. Formation of β-phenylethylamine in mammalian tissue and its effect on motor activity in the mouse. J. Pharmacol. Exp. Ther. 143:319–325.

    PubMed  CAS  Google Scholar 

  23. Sabelli, H. C., and Borison, R. L. 1976. 2-Pheylethylamine and other adrenergic modulators. Adv. Biochem. Psychopharmacol. 15:69–74.

    PubMed  CAS  Google Scholar 

  24. Fischer, E., Heller, B., and Miro, A. H. 1968. β-Phenylethylamine in human urine. Arzneimittelforsch 18, 1486.

    PubMed  CAS  Google Scholar 

  25. Yaryura-Tobias, J. A. 1979. Use of D- in the treatment of depression. In: Phenylethylamine: Biochemical Mechanism and Clinical Aspect, 489–508, Marcel Dekker, New York.

    Google Scholar 

  26. Fischer, E., Heller, B., Nachon, M. N., and Spatz, H. 1975. Therapy of depression by phenylalanine. Arzmimittel-Forsch. 25, 132.

    CAS  Google Scholar 

  27. Mosmain, A. D., Inwang, E. E., and Sabelli, H. C. 1974. The influence of psychotropic drugs on the levels of endogeneous 2-pheylethylamine in rabbit brain. Biol. Psychiatry 8:227–237.

    Google Scholar 

  28. Ipar, O.J., Fisscher, E., Heller, B., and Nachon, M. N. 1974. Therapie de la depression con D-fenilalanina. Pren. Med. Argent. 61, 498.

    Google Scholar 

  29. Hashimoto, H., Nakajima, T., Nishimura, T., Kudo, Y., Takeda, Y., Nakao, M., Kanaya, H., and Horiguchi, Y. 1983. Metabolism of D-pheylalanine and its effects on concentrations of brain monoamines and amino acids in rats. A basic study on possibility of clinical use of D-pheylalanine as an antidepressent-. Folia Psychiatr. Neurol. Jpn. 37:137–143.

    PubMed  CAS  Google Scholar 

  30. Mann, J., Peselow, F. D., Snyderman, S., and Gershon, S. 1980. D-Phenylalanine in endogenous depression. Am. J. Psychiatry. 137:1611–1612.

    PubMed  CAS  Google Scholar 

  31. Blaschko, H., Burn, J. H., and Langemann, H. 1950. The formation of noradrenaline from dihydroxyphenylserine. Br. J. Pharmacol. 5:431–437.

    CAS  Google Scholar 

  32. Schmiterlöw, C. G. 1951. The formation in vivo of noradrenaline from 3,4-dihydroxyphenylserine (noradrenaline carboxylic acid). Br. J. Pharmacol. 6:127–134.

    Google Scholar 

  33. Sano, I., Hirai, M., Matsuoka, Y., and Nakajima, T. 1973. 3,4-Dihydroxyphenylserine, as the precursor amino acid of noradrenaline. Bulletin of the Japanese Neurochemical Society (in Japanese). 12:96–98.

    Google Scholar 

  34. Pletscher, A. 1973. Aromatic amino acids as precursor for catecholamines. Fourth International Meeting of the International Society for Neurochemistry, Aug. 26–31, Tokyo, Japan., 104 (Abstract).

  35. Hirai, M., Matsuoka, Y., Nakafima, T., and Sano, I. 1975. Effect of 3,4-dihydroxyphenylserine on the concentration of brain noradrenaline and level of growth hormone of rats. Med. J. Osaka Univ. 26:51–59.

    PubMed  CAS  Google Scholar 

  36. Porter, C. C., Torchina, M. L., and Ston, C. A. 1972. (s)-Noradrenaline in the tissues of mice and rats given racemic erythro-3,4-dihydroxyphenylserine (DOPS). Life Sci. 11:787–797.

    Article  CAS  Google Scholar 

  37. Creveling, C. R., Daly, J., Tokuyama, T., and Witkop, B. 1968. The combined use of L-methyltyrosine and threo-dihydroxyphenylserine-selective reduction of dopamine levels in the central system-. Biochem. Pharmacol. 17:65–70.

    Article  PubMed  CAS  Google Scholar 

  38. Mori, T., Nakajima, T., Hashimoto, H., Noto, T., and Kato, N. 1985. Effect of DL-erythro-dihydroxyphenylserine on the locomotor activity of the mouse. Pharmacol. Biochem. Behav. 22:979–983.

    Article  PubMed  CAS  Google Scholar 

  39. Mori, M., Hashimoto, H., Fukui, K., Mori, T., Noto, T., and Nakajima, T. 1987. Effects of L-erythro-3,4-dihydroxyphenylserine on sleep-wakefulness patterns and concentrations of brain catecholamines and serotonin in rats. Jpn. J. Psychiatry Neurol. 41: 301–310.

    PubMed  CAS  Google Scholar 

  40. Van Praag, H. M. 1978. Amine hypothesis of affective disorders. In: Handbook of Psychopharmacology, ed. by Iversen L. L., Iversen S. D., and Snyder S. H., Vol. 13, 187–297, Plenum Press, New York and London.

    Google Scholar 

  41. Suzuki, T., Tsuge, I., Higa, S., Havashi, A., Yamamura, Y., Takaba, Y., and Nakajima, A. 1979. Catecholamine metabolism in familial amyloid polyneuropathy. Clin. Genetics. 16:117–124.

    Article  CAS  Google Scholar 

  42. Suzuki, T., Higa, I., Sakoda, S., Hayashi, A., Yamamura, Y., Takaba, Y., and Nakajima, A. 1981. Orthostatic hypotension in familial amyloid polyneuropathy: Treatment with DL-threo-3,4-dihydroxyphenylserine. Neurology. 31:1332–1326.

    Google Scholar 

  43. Birkmayer, W., Birkmayer, G., Lechner, H., and Riederer, P. 1983. DL-3,4-threo-DOPS in Parkinson's disease: Effects on orthostatic hypotension and dizziness. J. Neural Transm. 58:305–313.

    Article  PubMed  CAS  Google Scholar 

  44. Nagatsu, T., Kato, T., Numata, Y., Ikuta, K., Sano, M., Nagatsu, I., Kondo, Y., Inagaki, S., Iizuka, R., Hori, A., and Narabayashi, H. 1977. Phenylethanolamine N-methyltransferase and other enzymes of catecholamine metabolism in human brain. Clin. Chim. Acta. 75:221–232.

    Article  PubMed  CAS  Google Scholar 

  45. Narabayashi, H., Kondo, T., Hayashi, A., Suzuki, T., and Nagatsu, T. 1981. L-threo-3,4-Dihydroxyphenylserine treatment for akinesia and freezing of parkinsonism. Proc. Japan Acad. 57, Ser. B, 351–354.

    Google Scholar 

  46. Kondo, T. 1984. Effects of DL-threo-3,4-dihydroxyphenylserine on Parkinson's disease and pure akinesia. Clinical Neurol. (in Japanese). 24:280–288.

    CAS  Google Scholar 

  47. Inagaki, N., Yamatodani, A., and Wada, H. 1989. Histaminergic neuronal system in the brain-morphology and function-. In Endogenous Neuroactive Substances (ed. Yoshido H.) Chugai-Igakusha, Tokyo, pp. 279–291 (in Japanese).

    Google Scholar 

  48. Pyman, F. L. 1916. Derivatives og glyoxaline-4(or 5)-carboxylic acid. A new synthesis of histidine. J. Chem. Soc. 109:186–202.

    CAS  Google Scholar 

  49. Bargar, G., and Dale, H. H. 1910. Chemical structure and sympathomimetic action of amines. J. Physiol. 41:19–59.

    Google Scholar 

  50. Hasegawa, T. 1991. Studies on the formation of β-hydroxyhistamine and its action on histamine receptor in mammals. J. Kyoto Pref. Univ. Med. (in Japanese). 100:819–830.

    CAS  Google Scholar 

  51. Kamimura, H., Hasegawa, T., and Nakajima, T. 1989. Formation of β-hydroxyhistamine from β-hydroxyhistidine in rat organs and characterization of its synthetic enzyme prepared from rat stomach. Biomedical Research 10 (Suppl. 3). 241–250.

    CAS  Google Scholar 

  52. Yamada, M., Watanabe, T., Harino, S., Fukui, H., and Wada, H. 1980. The effects of protease inhibitors on histidine decarboxylase activities and assay of enzyme in various rat tissues. Biochim. Biophys. Acta 615:458–464.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neuropsychiatry, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyoku, 602, Kyoto, Japan

    Teruo Nakajima

Authors
  1. Teruo Nakajima
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Special issue dedicated to Dr. Kinya Kuriyama.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nakajima, T. Amine precursor amino acid therapy: From neurochemical basis to clinical aspects. Neurochem Res 21, 251–258 (1996). https://doi.org/10.1007/BF02529142

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02529142

Key Words

Search

Navigation